{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-124681","form_type":"8-K","ticker":"SLS","cik":"0001390478","company_name":"SELLAS Life Sciences Group, Inc.","filed_at":"2023-12-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.835139+00:00","generated_at":"2026-06-07T15:29:40.197677+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"SELLAS receives Nasdaq deficiency notice for market value below $35M minimum","bullets":["Nasdaq notified SLS on Dec 6, 2023 that MV of common stock was below $35M for 30 consecutive business days.","Company has 180 calendar days, until June 3, 2024, to regain compliance under Nasdaq Listing Rule 5810(c)(3)(C).","To regain compliance, market value must be at least $35M for 10 consecutive business days during the period.","Failure to comply by June 3, 2024 may lead to delisting, subject to appeal to a Nasdaq Hearings Panel.","SLS stock remains listed on Nasdaq Capital Market under symbol SLS at this time."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-124681","json":"https://secwatch.observer/filing/0001104659-23-124681.json","markdown":"https://secwatch.observer/filing/0001104659-23-124681.md","text":"https://secwatch.observer/filing/0001104659-23-124681.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1390478/000110465923124681/0001104659-23-124681-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1390478/000110465923124681/tm2332442d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T15:29:40.197677+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"fc3331490543709028024f8230768c9dc865dfba","claim":"SELLAS Life Sciences Group, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5550(b)(2), 5810(c)(3)(C)).","evidence_excerpt":"December 6, 2023, SELLAS Life Sciences Group, Inc. (the “Company”) received a letter from The Nasdaq Stock Market (“Nasdaq”) notifying the Company that it no longer meets Nasdaq’s requirements for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(2) (the “MVLS Rule”) because, for a period of 30 consecutive business days, the market value of the Company’s common stock, calculated based upon the most recent total shares outstanding multiplied by the closing bid price per share, has not maintained a minimum of $35.0 million. The letter does not impact the Company’s","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1390478/000110465923124681/0001104659-23-124681-index.htm","confidence":0.99,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"deficiency notice"},{"label":"Deficiency","value":"market value"},{"label":"Rules","value":"5550(b)(2), 5810(c)(3)(C)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}